Full text
Hypercalcemia of malignancy (HCM) is a serious metabolic complication, with the highest rates reported in multiple myeloma (MM).1,2 HCM occurs as the result of humoral mechanisms, such as parathyroid hormone‐related protein (PTHrP)‐ or 1,25‐dihydroxy vitamin D (1,25(OH)2D)‐mediated pathways and direct bone metastasis.3,4 Local osteolytic bone lesions are generally believed to be the main reason for hypercalcemia in patients with MM, and humoral hypercalcemia predominantly occurs in patients with squamous cell, renal cell, or ovarian cancer.5–13 Nevertheless, little is known about the proportion of hypercalcemia caused by HHM or local osteolysis in MM. Indeed, literature on the association between hypercalcemia and bone metabolism in patients with MM is lacking. In the older Durie and Salmon staging system, hypercalcemia was associated with a poorer prognosis,14 but it was not included in the international prognostic scoring system (ISS) or the revised ISS (R‐ISS) system.15,16 Recently, Zagouri et al showed that hypercalcemia remains a poor prognostic factor in the era of novel agents.17
In this study, we aimed to identify the main factors influencing hypercalcemia by examining clinical and mineral bone metabolism biochemical markers; we also analyzed the effect of hypercalcemia on the survival of patients with newly diagnosed multiple myeloma (NDMM).
The retrospective analysis included 357 consecutive unselected newly diagnosed patients with symptomatic MM treated within the Department of Hematology in Beijing Jishuitan Hospital between February 2013 and December 2019. The median follow‐up time was 24 months (5‐86 months), with follow‐up ending in April 2020. Hypercalcemia was defined as a serum calcium level >2.75 µmol/L and anemia as a hemoglobin level <10.0 g/dL. Renal failure was defined as creatine ≥177 µmol/L. Bone lesions were defined as one or more osteolytic lesions identified by skeletal radiography, computed tomography (CT), 18F‐fluorodeoxyglucose positron emission tomography with computed tomography (PET‐CT), or magnetic resonance imaging (MRI) according to the International Myeloma Working Group (IMWG) criteria.18 The ISS classification was used for the staging of all patients; 257 of the cases were examined using fluorescence in situ hybridization (FISH). The R‐ISS was applied for a subgroup of 325 patients. An analysis of overall survival (OS) was also performed. The database used is maintained at the Department of Hematology in Jishuitan Hospital; approval from the Scientific Committee/Institutional Review Board of Alexandra Hospital was obtained for the publication of these data, which are available upon request. In this retrospective study, laboratory data (biochemical, hematological, and electrophoretic results) obtained at the time of diagnosis were extracted from patients’ medical records; the data were analyzed after patient anonymization.
Patients up to 65 years of age and in good clinical condition received four cycles of bortezomib‐ or thalidomide‐based induction regimens, such as VAD, VTD, VCD, or TAD (VAD: bortezomib 1.3 mg/m2, administered intravenously on days 1, 8, 15, and 22; dexamethasone 40 mg, administered intravenously on days 1 through 4, 8, 15, and 22; pegylated liposomal doxorubicin 25 mg/m2, administered intravenously on day 1. VTD: bortezomib 1.3 mg/m2, administered intravenously on days 1, 8, 15, and 22; dexamethasone 40 mg, administered intravenously on days 1 through 4, 8, 15, and 22; thalidomide 100 mg po qn; VCD: bortezomib 1.3 mg/m2, intravenously on days 1, 8, 15, and 22; CTX 300 mg/m2, intravenously on days 1, 8, and 15; dexamethasone 40 mg, on days 1‐4, 8, 15, and 22. TAD: thalidomide 100 mg po qn; pegylated liposomal doxorubicin 25 mg/m2 on day 1; dexamethasone 40 mg on days 1‐4, 8, 15, and 22). Patients who achieved PR underwent stem cell mobilization with cyclophosphamide and granulocyte colony‐stimulating factor, followed by high‐dose melphalan and ASCT. Consolidation therapy typically consists of two to four cycles of a repeated induction regimen, which aims to improve the degree of response after transplant. Lenalidomide maintenance was considered to be post‐ASCT for all patients.
Among transplant‐ineligible patients, which are usually older and might be considered unsuitable owing to comorbidities, disability, or disease burden, they continuously received VD or a reduced‐intensity regimen of VAD or TAD and then lenalidomide maintenance for those with above VGPR.
Treatment options for refractory and relapsed cases include retreating with a previously used agent, switching to another agent in the same drug class, or switching to an agent in a different drug class. Additionally, BD‐PACE, RD‐PACE, BRD, MPV, and BTD were selected for salvage therapy of RRMM.
For patients with hypercalcemia, the conventional therapy included venoclysis of 5% glucose solution to hydration, sodium bicarbonate to alkalinize the urine and the use of a diuretic. Patients without renal dysfunction also received bisphosphonate treatment. The most effective treatment for MM is chemotherapy.
Blood samples for MM diagnosis in the study were collected within 72 hours. Drawn in the early morning on the hospital ward, all blood samples were analyzed at the Jishuitan Hospital Laboratory according to the manufacturer's protocol. Plasma P1NP, βCTX, Osteocalcin, total vitamin D, and PTH levels were measured using electrochemiluminescence immunoassays (Roche Diagnostics GmbH, Sandhofer Strasse 116). The inter‐/intra‐assay coefficients of variation in plasma βCTX was between 0.010 ng/ml and 6.00 ng/ml. The assay range of plasma P1NP was 5 ng/ml to 1200 ng/ml, that of plasma osteocalcin was 0.500 ng/ml to 300 ng/ml, that of plasma vitamin D total was 3.00 ng/ml to 70.0 ng/ml, and that of plasma PTH was 1.20 ng/ml to 5000 ng/ml.
Differences between mean values were evaluated by both Student's t and Mann–Whitney tests, and p values <0.05 were considered significant. Comparisons of categorical variables among different groups were carried out using the chi‐square test or Fisher's exact test when appropriate. Pearson correlation analysis was performed to assess linear correlation between two parameters. OS was measured from the date of treatment initiation until the date of death or the date of the last follow‐up. Time to event curves were plotted with the Kaplan–Meier method, and comparisons among groups were conducted using the log‐rank test. For multivariate analysis, factors associated with time to event were introduced into a Cox proportional hazards model. SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis. A p‐value of <0.05 was considered statistically significant.
The baseline characteristics of the patients with NDMM are described in Table 1. Using the IMWG definition, 16.8% (60/357) of the patients with symptomatic MM had hypercalcemia (i.e., serum calcium ≥2.75 µmol/L) at the time of diagnosis. The presence of hypercalcemia was strongly associated with features of advanced disease, including β2 microglobulin, hemoglobin, creatinine, uric acid, phosphorus, ISS stage, and R‐ISS stage (p < 0.01 for all comparisons) (Tables 2 and 3 and Figure 1). Among the 357 patients, 52 (14.6%) had renal insufficiency, among whom 31 (59.6%) had hypercalcemia. In our study, 91.2% of patients had lytic bone lesions identified by imaging, such as MRI, CT, and PET‐CT. In the subgroup of patients with available cytogenetic data (N = 257), there were no differences between those with hypercalcemia and without hypercalcemia (Table 3).
TablePatient characteristics| Characteristics | N. |
| No. of patients | 357 |
| Median age, range | 60 (27‐89) |
| Male (%) | 199 (55.7) |
| M protein (%) | |
| IgG | 153 (42.8) |
| IgA | 86 (24.1) |
| IgD | 14 (3.9) |
| Light chain | 94 (26.3) |
| No secreted | 10 (2.9) |
| ISS (%) | |
| I | 117 (32.8) |
| II | 109 (30.5) |
| III | (131 36.7) |
| R‐ISS (%) | |
| I | 71 (21.8) |
| II | 193 (59.4) |
| III | 61 (18.8) |
| Failed in Staging* | 32 (8.9%) |
| Frequency of CRAB features (%) | |
| Hypercalcemia | 60 (16.8) |
| Renal dysfunction | 52 (14.6) |
| Anemia | 219 (61.4) |
| Bone disease | 325 (91.2) |
| Median follow‐up, months (range) | 24 (1‐82) |
|
Patients with hypercalcemia (N = 60) |
Patients without hypercalcemia (N = 297) | p‐value | |
| Sex (male/female) | 34/26 | 165/132 | 0.888 |
| Age (median/range) | 58 (41‐83) | 61 (27‐89) | 0.748 |
| Hemoglobin, g/L | 83 (48‐158) | 109 (31‐174) | <0.001 |
| β2 microglobulin, mg/L | 7.175 (1.73‐54.38) | 3.92 (1.13‐52.01) | 0.002 |
| Creatinine, umol/L | 186 (54‐812) | 71 (28‐1104) | <0.001 |
| Phosphorus, mmol/L | 1.38 (0.74‐5.59) | 1.28 (0.56‐2.3) | <0.001 |
| Uric acid, umol/L | 522.5 (7‐1076) | 378 (10‐803) | 0.006 |
| LDH, IU/L | 166 (88‐488) | 171.5 (38‐940) | 0.244 |
| ALP, IU/L | 76 (30‐216) | 70 (26‐640) | 0.871 |
| tP1NP, ng/ml | 86.5 (2.45‐362) | 63.47 (13.38‐546.5) | 0.277 |
| β‐CTX, ng/ml | 2.22 (0.2‐5.29) | 0.73 (0.07‐3.57) | 0.001 |
| OC, ng/ml | 29.45 (7.25‐161.2) | 18.56 (3.7‐190.7) | <0.001 |
| 25‐(OH)2D3, ng/ml | 12.6 (3‐69.87) | 15.33 (2.0‐47.26) | 0.002 |
| PTH, pg/ml | 11.9 (3.8‐99) | 28.2 (4.6‐20.3) | 0.024 |
| Patients with hypercalcemia, N = 60 | Patients without hypercalcemia, N = 297 | p‐value | |
| del13q (by FISH) | 18 (30.2) | 95 (32.0) | 0.860 |
| amp1q21 | 14 (23.2) | 62 (20.9) | 0.838 |
| del17p | 12 (20.9) | 54 (18.6) | 0.831 |
| t(4;14) | 8 (13.9) | 26 (8.8) | 0.394 |
| t(14;16) | 4 (6.9) | 18 (6.0) | 1.0 |
| t(11;14) | 10 (16.3) | 54 (18.1) | 0.832 |
| High‐risk FISH | 25 (41.8) | 107 (36.3) | 0.605 |
| ISS stage | 0.000 | ||
| I | 4 (6.7) | 98 (38.0) | |
| II | 8 (13.3) | 101 (34.0) | |
| III | 48 (80) | 83 (28) | |
| R‐ISS stage | 0.000 | ||
| I | 1 (2.0) | 66 (22.2) | |
| II | 33 (55.1) | 157 (52.8) | |
| III | 26 (42.9) | 42 (14.1) | |
| Failed in Staging * | 0 | 32 (10.9) |
Enlarge this image.1 Figure. Increased serum phosphonate, creatinine, and uric acid levels correlate with hypercalcemia in MM patients (p < 0.001)
Serum levels of β‐CTX, tPINP, and osteocalcin (OC) were significantly elevated but PTH levels significantly decreased in patients with hypercalcemia (Table 2, Figure 2). Serum alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels were not associated with calcium abnormalities (Table 2). Furthermore, Patients presented of lytic bone lesion had a higher level of tP1NP than patients without osteolytic disease (68.25 ng/ml vs 50.04 ng/ml, p = 0.035, data not shown).
Enlarge this image.2 Figure. Increased serum tPINP, β‐CTX, and OC levels and decreased serum PTH level correlate with hypercalcemia in MM patients (p < 0.001)
When multivariate analysis was performed using serum levels of hemoglobin, phosphorus, β‐CTX, tPINP, OC, 25‐(OH)2D3, PTH, creatinine, and uric acid, laboratory parameters (PTH, creatinine, uric acid, and hemoglobin) were found to be the most important factors of hypercalcemia (Table 4).
TableLogistic regression of multivariate analysis for hypercalcemia| Exp (B) | 95% CI for EXP (B) | Sig | ||
| Lower | Upper | |||
| PTH | 0.967 | 0.943 | 0.992 | 0.006 |
| CRE | 1.006 | 1.003 | 1.010 | 0.001 |
| Uric acid | 1.005 | 1.002 | 1.008 | 0.001 |
| Hemoglobin | 0.978 | 0.962 | 0.993 | 0.005 |
Among the 60 patients with hypercalcemia, mild hypercalcemia (serum calcium 11‐12 mg/dl, 2.75–3.0 mmol/L) accounted for 35%, moderate hypercalcemia (serum calcium 12–14 mg/dl, 3–3.5 mmol/L) for 46.7%, and severe hypercalcemia (serum calcium>14 mg/dl, >3.5 mmol/L) for 18.3%. The degree of hypercalcemia was closely associated with renal failure, and the proportion of mild, moderate, and severe hypercalcemia patients with renal failure was 23.8%, 60.7%, and 81.8%, p = 0.001, respectively (Table 5). Forty percent of patients with hypercalcemia had normal or mildly elevated PTH levels.
TableRelationship between the degree of hypercalcemia and renal failure in 60 cases| Classification of hypercalcemia | n | Renal failure, n (%) | p |
| Mild (2.75‐3 mmol/L) | 21 | 5 (23.8) | 0.001 |
| Moderate (3‐3.5 mmol/L) | 28 | 17 (60.7) | |
| Severe (>3.5 mmol/L) | 11 | 9 (81.8) |
According to univariate analysis, the presence of hypercalcemia was associated with significantly inferior survival (36.3 months vs 56.8 months, p = 0.019). We examined the prognostic impact of hypercalcemia in a multivariate model that also included established prognostic factors (ISS stage, R‐ISS stage, age, high‐risk FISH findings), and hypercalcemia remained an independent poor prognostic factor (HR: 1.854, 95% CI: 1.006‐3.415, adjusted p = 0.048) (Table 6, Figure 3).
TableMultivariate analysis for myeloma OS| Variable | Hazard ratio (HR) | 95% CI for HR | p‐value |
| Age >65 | 2.628 | 1.559‐4.430 | 0.000 |
| Hypercalcemia | 1.854 | 1.006‐3.415 | 0.048 |
| R‐ISS | 1.952 | 1.254‐3.038 | 0.003 |
Enlarge this image.3 Figure. Survival comparison between multiple factors. (A) With age greater than or equal to 65 years or less than 65 years, the median OS was 65 months vs 35 months, respectively (p = 0.000). (B) With hypercalcemia and no hypercalcemia, the median OS was 60 months vs 39 months, respectively (p = 0.019). (C) With R‐ISS stage I, II, and III, the median OS was not reached at 66 months or 36 months (p = 0.017)
Early death occurred in 18.33% and 8.41% of patients with and without hypercalcemia, respectively (p = 0.048).
The bone remodeling process, intestinal absorption, and renal tubule resorption are the three main metabolic pathways that contribute to maintaining the serum calcium concentration in a narrow physiological range. Hyper‐ or hypocalcemia occurs due to imbalances in these regulatory pathways. HCM is the most common cause of hypercalcemia, which is a potentially life‐threatening but relatively common clinical problem.19,20 Serum calcium is tightly regulated by interactions between PTH and (1,25(OH)2D), which modulate calcium movement at the level of the bone, kidneys, and intestines.21 Local osteolytic hypercalcemia and PTHrP‐ and/or 1,25(OH)2D‐induced disorder are the two main reasons for HCM. In patients with localized, as well as generalized, myeloma bone disease, bone destruction, together with a lack of bone formation, results in excess bone resorption and causes excessive release of calcium, leading to hypercalcemia.22 Osteoclast‐activating factors stimulate bone resorption through nuclear factor kappa B ligand (RANKL), macrophage inflammatory protein 1α, interleukin 6, and tumor necrosis factor α signaling, causing recruitment of additional osteoclasts and increased calcium release into the circulation.23,24
Unfortunately, to date, there are no reports on the association between hypercalcemia and the amount or degree of bone damage in patients with MM. In our study, patients with bone destruction accounted for 91.2% of all patients; the vast majority of patients had more than 3‐5 lesions, though only 16.8% of patients had hypercalcemia. Thus, hypercalcemia mainly caused by localized bone disease could not well explain our clinical results. The presence of hypercalcemia was associated with higher serum levels of β‐CTX, which reflects bone resorption, or tPINP and OC, which reflect bone formation. Nonetheless, β‐CTX and OC were not significant factors in multivariate analysis. This result indicates that although local bone lesions are related to hypercalcemia, they are not the most important factors for hypercalcemia. We think that humoral hypercalcemia is still the main cause of hypercalcemia in MM. On the other hand, both 25‐(OH)2D3 and PTH levels were significantly decreased in patients with hypercalcemia compared with patients without hypercalcemia. Among the 357 patients with NDMM, 14.6% had renal failure, and 59.6% with renal failure had hypercalcemia. Serum levels of phosphorus, creatinine, and uric acid were significantly increased in patients with hypercalcemia compared with patients without hypercalcemia. PTH, hemoglobin, creatinine, and uric acid were the factors most closely related to hypercalcemia in multivariate analysis. Hypercalcemia may develop in patients with osteoporosis and treated with recombinant PTH (1‐84), and serum calcium correlates with urinary calcium excretion, serum ALP, and β‐CTX in these patients.25
In particular, kidney impairment accounted for 81.8% of patients with severe hypercalcemia (serum calcium >3.5 mmol/L), further indicating the important role of the kidneys in hypercalcemia. Due to the excessive deposition of immunoglobulin in patients with MM, renal tubular function is often impaired, which leads to increased calcium reabsorption by renal tubules. Subsequently, the ability of the kidney to effectively remove excessive calcium from the circulation is hampered, resulting in elevated serum calcium, which may lead to severe hypercalcemia and renal failure. In addition, hemoglobin had a faint effect on hypercalcemia, as shown in Table 3. We hypothesize that anemia is indirectly related to hypercalcemia, as hemoglobin correlated negatively with serum creatinine (p < 0.001, data not shown).
Overall, we think that although bone destruction is a characteristic change in MM, serum calcium is still regulated by internal secretion. Although the reasons for hypercalcemia are manifold, among them, humoral hypercalcemia may be highly important. Unfortunately, we only retrospectively analyzed bone turnover metabolism and biochemical markers and did not detect PTHrP. Despite the lack of PTHrP analysis, previous studies have confirmed that PTHrP produced by plasma cells in MM regulates their survival and pro‐osteoclast activity, promoting bone disease progression.26–30
The presence of hypercalcemia was strongly associated with features of advanced disease, such as β2 microglobulin, ISS stage, and R‐ISS stage. Our results are consistent with those of many previous studies showing that hypercalcemia is a factor for a poor prognosis.31,32 However, the presence of hypercalcemia is not included in the ISS stage or the R‐ISS stage, though it was an inferior prognostic factor in the original dataset.16 In our study, we found that hypercalcemia, age greater than 65 years old, and R‐ISS stage were three independent prognostic factors affecting the survival of MM patients.
In our patient population, hypercalcemia was associated with a significantly higher early mortality rate than no hypercalcemia, with rates of 18.33% vs 8.41%. This result is consistent with that reported by Zagouri et al.17 Indeed, early mortality is a major barrier to the treatment of MM.33 Therefore, patients with a high risk of early mortality should be identified early and managed appropriately.
In our study, which was based on a single‐center database of consecutive, unselected patients, thalidomide‐containing or bortezomib‐based antimyeloma therapy was used in patients presenting with hypercalcemia. The symptoms and serum calcium level of all patients with hypercalcemia improved quickly within the first week after bisphosphonate application and chemotherapy. However, the use of these drugs did not alter the poor prognosis of patients with hypercalcemia.
Our study based on patients with symptomatic NDMM at a single center showed that hypercalcemia is associated with poor survival and is caused by manifold factors with humoral effects and local bone destruction.
This work was supported by Wu Jieping Medical Foundation (grant no. 320‐6750‐18309), Beijing Municipal Excellent Talents Foundation (grant no. 2018000021469G223), and Beijing JST Research Funding (grant no. QN‐201908).
The authors have no conflicts of interest to disclose.
L. B designed the study; Y.‐T.W. collected the data; L. B analyzed the data and wrote the manuscript. All authors contributed to the interpretation of the data, prepared the manuscript, and approved the final version.
The analysis data and models we used during the study are available from the corresponding author by request.
© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Wang, Yutong 1 ; Lu, Minqiu 1 ; Chu, Bin 1 ; Shi, Lei 1 ; Gao, Shan 1 ; Fang, Lijuan 1 ; Qiuqing Xiang 1 1 Department of Hematology, Beijing Jishuitan Hospital, Beijing, China